Ibrutinib: A narrative drug review

• Published in: Cancer Research, Statistics, and Treatment Vol. 3; no. 4; pp. 767 - 784
• Main Authors: Munot, PriteshNaresh, Mirgh, Sumeet, Mehra, Nikita, Bagal, BhausahebP
• Format: Journal Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 01.01.2020
• Subjects: chronic lymphocytic lymphoma; ibrutinib; mantle cell lymphoma; primary central nervous system lymphoma; waldenstrom's macroglobulinemia
• ISSN: 2590-3233; 2590-3225
• DOI: 10.4103/CRST.CRST_234_20

Ibrutinib is an oral, irreversible covalent inhibitor of the Bruton tyrosine kinase, that plays a major role in B-cell differentiation, proliferation, migration, survival, and apoptosis. It has been found to be active against a number of B-cell malignancies. Ibrutinib has shifted the treatment strategy for malignancies away from cytotoxic chemotherapies toward a more targeted approach. It has already been approved for a number of B-cell malignancies such as mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, and chronic graft-versus-host disease in allogeneic stem cell transplant recipients, and still continues to be evaluated for a number of other B-cell malignancies in various settings. We comprehensively searched the PubMed database to identify and compile the current scenarios in which ibrutinib is indicated for use in oncological practice.